Introducing a novel chemotherapeutic drug formulated with anthraflavic acid for treating human breast carcinoma and type 2 diabetes mellitus

Gang Zhao¹, Arunachalam Chinnathambi², Tahani Awad Alahmadi³, Milton Wainwright⁴

¹Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin, China
²Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia
³Department of Pediatrics, College of Medicine and King Khalid University Hospital, King Saud University, Medical City, Riyadh, Saudi Arabia
⁴Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield, UK

Submitted: 28 May 2021; Accepted: 10 August 2021
Online publication: 24 August 2021

Arch Med Sci 2023; 19 (6): 1850–1858
DOI: https://doi.org/10.5114/aoms/141173
Copyright © 2021 Termedia & Banach

Abstract

Introduction: Molecular docking as a versatile theoretical method was used to investigate the biological activities of anthraflavic acid in the presence of α-amylase. The outcomes revealed that anthraflavic acid has a considerable binding affinity to the enzyme with a docking score of −7.913 kcal/mol. These outcomes were further evaluated with free binding energy calculations, and it was concluded that anthraflavic acid could be a potential inhibitor for α-amylase.

Material and methods: Anthraflavic acid was explored in anti-human breast carcinoma tests. The in vitro cytotoxic and anti-breast carcinoma effects of biologically synthesized anthraflavic acid against MCF-7, CAMA-1, SK-BR-3, MDA-MB-231, AU565 [AU-565], and Hs 281.T cancer cell lines were assessed. In the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, the anti-breast carcinoma properties of anthraflavic acid could significantly kill the MCF-7, CAMA-1, SK-BR-3, MDA-MB-231, AU565 [AU-565], and Hs 281.T cancer cell lines in a time- and concentration-dependent manner. Also, we used human umbilical vein endothelial cells (HUVECs) to determine the cytotoxicity potentials of anthraflavic acid using MTT assay.

Results: The IC₅₀ values of anthraflavic acid were 159, 193, 253, 156, 241, and 218 µg/ml against MCF-7, CAMA-1, SK-BR-3, MDA-MB-231, AU565 [AU-565], and Hs 281.T cancer cell lines.

Conclusions: It seems the anti-human breast carcinoma effect of recent nanoparticles is due to their antioxidant effects.

Key words: anthraflavic acid, α-amylase, human breast carcinoma, cytotoxic, molecular docking.

Introduction

One of the many anthraquinones with potential antimutagenic activity is anthraflavic acid (2,6-dihydroxyanthraquinone). This compound has been shown to markedly inhibit the mutagenicity of 7,8-dihydroxy-9,10-epoxybenzo[a]pyrene, the ultimate mutagen/carcinogen of benzo[a]pyrene, in the Ames test, presumably by the formation of
Introducing a novel chemotherapeutic drug formulated with anthraflavic acid for treating human breast carcinoma and type 2 diabetes mellitus

Material and methods

Material

Phosphate buffer solution (PBS), 4-(dimethylamino)benzaldehyde, Ehrlich solution, dimethyl sulfoxide (DMSO), Dulbecco’s Modified Eagle Medium (DMED), hydrolysate, decamplmaneh fetal bovine serum, borax-sulfuric acid mixture, 2,2-dimethyl-1,4-glycosidic linkages are α(GH-13). In starch, α-1,4-glycosidic linkages are hydrolyzed by amylases, so they are known as glycoside hydrolases [2, 3].

In the present study, also the properties of anthraflavic acid against common breast carcinoma cell lines, i.e. MCF-7, CAMA-1, SK-BR-3, MDA-MB-231, AU565 [AU-565], Hs 281.T, and anti-diabetic action were evaluated with molecular docking.

Anti-human breast carcinoma properties of anthraflavic acid

In this research, we used human umbilical vein endothelial cells (HUVECs) to determine the cytotoxicity potential of anthraflavic acid (CAS number: 84-60-6, molecular weight: 240.21, EC number: 3.2.1.1, 0.5 mg/ml, prepared with 0.02 M sodium phosphate buffer (pH 6.9) with 0.006 M sodium chloride) were incubated at 25°C for 10 min. Then, 500 µl of 1% starch solution in 0.02 M sodium phosphate buffer (pH 6.9 with 0.006 M sodium chloride) was added to each tube [9]. The reaction mixture was incubated at 25°C for 10 min and stopped with 1.0 ml of dinitrosalicylic acid color reagent. Thereafter, the mixture was incubated in a boiling water bath for 5 min and cooled to room temperature. The reaction mixture was then diluted to 10 ml with distilled water, and absorbance was measured at 540 nm against distilled water blank. The experiment was repeated using acarbose as a standard antidiabetic drug (positive control). The α-amylase inhibitory activity was expressed as percentage inhibition [10].

Molecular docking study

In addition to some empirical investigations, the biological characteristics of chemical compounds could be examined using analytical methods such as a molecular docking study. The en-
zymes used in this study were human pancreatic α-amylase (PDB ID: 1HNY) [11]. The biological activities of anthraflavic acid and acarbose against this enzyme were evaluated using molecular docking. After obtaining the enzyme structure from the PDB database (http://wwrcsb.org/pdb), it was prepared with the protein preparation module of the Schrödinger Suite [12]. The hydrogen atoms were added to the enzyme structure, and the missing side chains were replaced using primers. The water molecules beyond 5Å from het groups were removed, and an H-bond network was created using the optimization step of the module. The minimization step was then applied for the structure using optimized potentials for liquid simulations (OPLS3e) force field. The binding sites of the enzyme were predicted using the Site-Map of Schrödinger to find the active sites of the structure [13]. The SDF files of anthraflavic acid and acarbose were obtained from the PubChem database and the correct molecular geometries were generated utilizing the LigPrep module of Schrödinger [14]. The Epic module was used to produce protonation states. Lastly, molecular docking was performed employing Glide of the Schrödinger Suite.

**Binding free energy calculations**

The binding free energy of the ligand-enzyme complex was calculated conducting the MM/GBSA method (Schrödinger Release 2020-2: Prime, Schrödinger, LLC, New York, NY, 2020-2) [15]. The solvation model of VSGB and OPLS3e force field were used for the calculations [16]. The equation of binding free energy is displayed here: \( \Delta G \text{bind} = G \text{complex} - (G \text{protein} + G \text{ligand}). \)

Where \( \Delta G \text{bind} \) indicates the binding free energy, \( G \text{complex} \) is the binding free energy. The \( G \text{protein} \) and \( G \text{ligand} \) indicate the binding free energy of the protein and ligand, respectively.

**Results and discussion**

**Cancer results**

Cancer is now one of the leading causes of death worldwide. Existing treatments have not been able to meet the treatment needs for various types of cancer. Therefore, the use of new technologies in the prevention and treatment of cancer can be helpful. Extensive research on molecules has been conducted in recent years [17, 18]. The advent of biotechnology has had a profound effect on many areas of healthcare and scientific research. Common cancer treatments, including chemotherapy, radiation and surgery, may reduce the size of the tumor, but the effect of these methods is transient and has no positive effect on patient survival. Therefore, replacing more effective, more specific therapies with fewer side effects with higher anti-cancer activity is a dominant issue in clinical oncology [19]. The gradual maturation of biotechnology has been considered not only for treating cancer but also for a wide variety of applications, especially for drug delivery and diagnostic and imaging cases. There are many types of molecules available and choosing the right carriers according to demand is a key issue [20–22]. Molecules are very close in size to biological molecules and can easily penetrate the cell; for this reason, one of the goals of biotechnology is to mount molecules and drugs on molecules and transfer them to the target cell [23, 24]. It is also possible to create different surface properties for molecules by attaching protective ligands to increase the molecules’ resistance to the immune system and increase their presence in the bloodstream, and even binding ligands to specifically bind the molecules to the target tissue [25–29].

One of the cytotoxicity test methods to measure the rate of cell death is the MTT method, which is based on the formation of formazan dye by reducing the substance MTT (dimethyl thiazole 2 and 5 diphenyltetrazolium bromide) or other tetrazolium salts [7]. Through breaking of the MTT tetrazolium ring by mitochondrial enzymes in living cells, insoluble purple formazan crystals are formed. The formation of these crystals indicates the activity of respiratory chain enzymes and is a measure of cell viability. By measuring the amount of absorption by spectrophotometry at specific wavelengths, the number of living cells can be determined. This test is performed according to ISO 10993-5 and its purpose is in vitro evaluation of cytotoxicity. The cytotoxicity test is performed according to the ISO10993-5 standard and in three ways: NRU test, CFU test, MTT test and XTT test. The most common method for assessing cytotoxicity is to measure cell survival by MTT [7]. The MTT method is based on the intensity of dye produced by the mitochondrial activity of cells, measured at a wavelength of 540 to 630 nm and directly proportional to the number of living cells; the increase or decrease in the number of living cells is linearly related to the activity of cell mitochondria. MTT tetrazolium dye is revived in active (metabolically) cells. Mitochondrial dehydrogenases in living cells produce NADH and NADPH, leading to an insoluble purple precipitate called formazan. This precipitate can be dissolved by isopropanol or dimethyl sulfoxide [7]. Dead cells, on the other hand, are unable to perform this conversion due to the inactivity of their mitochondria and therefore do not show a signal. In this method, dye formation is used as a marker for the presence of living cells. In recent
Introducing a novel chemotherapeutic drug formulated with anthraflavic acid for treating human breast carcinoma and type 2 diabetes mellitus

years, MTT testing has been the most important measurement method to evaluate the toxicity and anti-cancer effects of molecules [7].

In this study, cells treated with different concentrations of anthraflavic acid were assessed by MTT assay for 48 h as regards the cytotoxic properties on normal (HUVEC) and breast malignancy cell lines i.e. MCF-7, CAMA-1, SK-BR-3, MDA-MB-231, AU565 [AU-565], and Hs 281.T (Figures 1, 2).

The viability of the malignant breast cell line decreased dose-dependently in the presence of anthraflavic acid. The IC_{50} values of anthraflavic acid were 159, 193, 253, 156, 241, and 218 µg/ml for MCF-7, CAMA-1, SK-BR-3, MDA-MB-231, AU565 [AU-565], and Hs 281.T cell lines, respectively (Table I).

The absorbance rate was evaluated at 570 nm, representing viability on a normal cell line (HUVEC) even up to 1000 µg/ml for anthraflavic acid (Table I and Figures 1, 2).

Enzymes results

The enzymatic starch digestion process as affected by α-amylase inhibitors is complicated. To date, most of the factors affecting the inhibition have been revealed, including particle size, crystallinity, composition and structure of starch. Hydrogen bonds and a conjugated π-system were critical for flavonoid inhibitors to control starch digestion [30]. However, the contribution of hydrophobic interaction to the inhibitory mechanism has been scarcely studied. The important purpose of this study is to determine an efficacious, selective and more potent inhibitor for the enzyme α-amylase [31]. Hence, inhibition analysis of this enzyme was

Figure 1. Anti-human breast adenocarcinoma properties (cell viability (%)) of anthraflavic acid (concentrations of 0-1000 µg/ml) against human breast adenocarcinoma (MCF-7 (A), CAMA-1 (B), SK-BR-3 (C), and MDA-MB-231 (D)) cell lines. Numbers indicate the percentage cell viability at concentrations of 0–1000 µg/ml of anthraflavic acid for several human breast adenocarcinoma cell lines
recorded with anthraflavic acid to control diabetic complications. The IC$_{50}$ result for this compound was 198.30 nanomolar. Type 2 diabetes mellitus (T2DM) is characterized by elevated blood glucose levels and can lead to serious complications such as nephropathy, neuropathy, retinopathy and cardiovascular disease [32].

**Docking results**

The biological activities of anthraflavic acid as an inhibitor for α-amylase were investigated with molecular docking calculations. Acarbose was also considered as a validated standard inhibitor for α-amylase. The docking pose of anthraflavic acid is presented in Figure 3, and Figure 4 shows the interactions between various residues of the enzyme and anthraflavic acid. Figure 4 shows that an oxygen atom of the ligand has created two hydrogen bonds with Trp59 and Gln63. This oxygen atom is a hydrogen bond donor, forming hydrogen bonds with the oxygen of Trp and nitrogen of Gln. Trp59 is one of the common residues for anthraflavic acid and acarbose that has created interaction with the ligands. Another residue that has hydrophobic contact with anthraflavic acid is Glu233. This interaction is an important contact since Glu233 is a crucial member of the enzyme active site [33]. The presence of this contact among hydrophobic contacts could lead to inhibitory activity of this compound. Figure 5 shows the docking pose of acarbose among α-amylase residues, and their interactions are presented in Figure 6. As can be seen, acarbose is very active when contacting the enzyme and has created several hydrogen bonds and hydrophobic contacts. The parameters obtained from docking calculations are shown in Table II. The docking score indicates the binding affinity, which is the most important parameter [34]. The molecule’s efficiency is another essential parameter, numerically calculated and shown with the glide ligand efficiency. Glide evdw and glide ecoul are Van der Waals and Coulomb energy, respectively. These two parameters are interaction-related, and glide energy is calculated as a modification of their energy. The next parameter is glide emodel, which shows the value of the interaction pose [35]. Some of the obtained results of free binding energy are presented in Table III. As can be clearly seen, the docking scores have a positive correlation with the reported IC$_{50}$ of the compounds. This correlation is further supported by the value of binding energy, which is −19.36 for anthraflavic acid and −11.82 for acarbose. It can be concluded from these results that the predicted docking pose is reliable [36]. Due to the values presented in Table III, coulomb energy has a crucial role in the binding energies between the compounds and α-amylase. However, binding energies such as H-bond, lipophilic energy, covalent energy, and Van der Waals energy are important parame-

---

**Table I. IC$_{50}$ of anthraflavic acid in anti-human breast adenocarcinoma test**

| Variable | MCF-7 | CAMA-1 | SK-BR-3 | MDA-MB-231 | AU565 [AU-565] | Hs 281.T |
|----------|-------|--------|---------|-------------|----------------|-----------|
| IC$_{50}$ [µg/ml] | 159 ±0 | 193 ±0 | 253 ±0 | 156 ±0 | 241 ±0 | 218 ±0 |

---

**Figure 2.** Anti-human breast adenocarcinoma properties (cell viability (%)) of anthraflavic acid (concentrations of 0–1000 µg/ml) against human breast adenocarcinoma (AU565 [AU-565] (A) and Hs 281.T (B)) cell lines. Numbers indicate percentage cell viability at concentrations of 0–1000 µg/ml of anthraflavic acid for several human breast adenocarcinoma cell lines.
Introducing a novel chemotherapeutic drug formulated with anthraflavic acid for treating human breast carcinoma and type 2 diabetes mellitus.

Figure 3. Docking pose of anthraflavic acid among α-amylase residues.

Figure 4. Interactions of anthraflavic acid and α-amylase. Green dashed lines indicate hydrogen bonds, and semi-circles show hydrophobic contacts.
Figure 5. Docking pose of acarbose among α-amylase residues

Figure 6. Interactions of acarbose and α-amylase. Green dashed lines indicate hydrogen bonds, and semicircles show hydrophobic contacts
Introducing a novel chemotherapeutic drug formulated with anthraflavic acid for treating human breast carcinoma and type 2 diabetes mellitus

It is evident that all of these parameters have a key role in the interactions between the molecule and enzymes. Based on the results obtained from these molecular docking investigations, like acarbose, anthraflavic acid could be considered as a potential inhibitor for α-amylase. In conclusion, in this research, the viability of a malignant breast cell line was reduced dose-dependently in the presence of anthraflavic acid. The IC50 values of anthraflavic acid were 159, 193, 253, 156, 241, and 218 µg/ml for MCF-7, CAMA-1, SK-BR-3, MDA-MB-231, AU565 [AU-565], and Hs 281.T cell lines, respectively. After the clinical study, anthraflavic acid can be utilized as an efficient drug in treating breast carcinoma in humans.

Acknowledgments
This project was supported by Researchers Supporting Project number RSP-2021/230, King Saud University, Riyadh, Saudi Arabia.

Conflict of interest
The authors declare no conflict of interest.

References
1. Brown JP. A review of the genetic effects of naturally occurring flavonoids, anthraquinolines and related compounds. Mutation Res 1980; 75: 243-77.
2. Turesky RJ, Skipper DI, Tannenbaum SR. Sulforaphane formation is a major route for detoxification of 2-amino-3-methylimidazo[4,5-f]quinoline in the rat. Carcinogenesis 1986; 7: 1483-5.
3. Sayer JM, Yagi H, Wood AW, Conney AH, Jerina DM. Extreme facile reaction between the ultimate carcinogen benzo[a]pyrene 7,8-diol-9,10-epoxide and ellagic acid. J Am Chem Soc 1982; 104: 5562-4.
4. Koçyiğit ÜM, Taslimi P, Tüzün B, Yakan H, Muğlu H, Güzel E. 1,2,3-Triazole substituted phthalocyanine metal complexes as potential inhibitors for anticholinesterase and antidiabetic enzymes with molecular docking studies. J Biomol Struct Dyn 2022; 40; 4429-39.
5. Jhung CH, Riyaphan J, Lin SH, Chia YC, Weng CF. Screening alpha-glucosidase and alpha-amylase inhibitors from natural compounds by molecular docking in silico. BioFactors 2015; 41: 242-51.
6. Lyne PD, Lamb ML, Saeh JC. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem 2006; 49: 4805-8.
7. Zhang Y, Zhang X, Zhang L, Alarfaj AA, Hirad AH, Alsabri AE. Green formulation, chemical characterization, and antioxidant, cytotoxicity, and anti-human cervical cancer effects of vanadium nanoparticles: a pre-clinical study. Arab J Chem 2021; 14: 103147.
8. Adefegha SA, Oboh G. Inhibition of key enzymes linked to type 2 diabetes and sodium nitroprusside-induced lipid peroxidation in rat pancreas by water extractable phytochemicals from some tropical spices. Pharm Biol 2012; 50: 857-65.
9. Rahim F, Tariq S, Taha M, et al. New triazinoindole bearing thiazole/oxazole analogues: synthesis, α-amylase inhibitory potential and molecular docking study. Bioorg Chem 2022; 106564.
10. Brayer GD, Luo Y, Withers SG. The structure of human pancreatic α-amylase at 1.8 Å resolution and comparisons with related enzymes. Protein Sci 1995; 4: 1730-42.
11. Schrödinger Release 2020-4: Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY.
12. Schrödinger Release 2020-4: LigPrep, Schrödinger, LLC, New York, NY.
13. Poustforoosh A, Hashemipour H, Tüzün B, Pardakhty A, Mehrabani M, Nematollahi MH. Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods. Biophys Chem 2021; 272; 106564.
14. Schrödinger Release 2020-4: Schrödinger, LLC, New York, NY.
15. Nikalje APG, Shaikh AN, Shaikh SI, Khan FAK, Sangshetti JN, Shinde DB. Microwave assisted synthesis and docking study of N-(2-oxo-2-(4-oxo-2-substituted thi-
azolidin-3-ylaminoo) ethyl benzamide derivatives as anticonvulsant agents. Bioorg Med Chem Lett 2014; 24: 5558-62.
16. Wang SM, Zha GF, Rakesh K, et al. Synthesis of benzo[de]thiazole-hydrazine analogues: molecular docking and SAR studies of potential H+/K+ ATPase inhibitors and anti-inflammatory agents. Med Chem Comm 2017; 8: 1725-39.
17. Xinli DHZS. Applications of nanocarriers with tumor molecular targeted in chemotherapy. Chemistry 2012; 75: 621-7.
18. Yang F, Jin C, Jiang Y, et al. Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev 2011; 37: 633-42.
19. Mohammed MI, Makky AM, Teaima MH, Abdellatif MM, Hamzawy MA, Khalil MA. Transdermal delivery of vancomycin hydrochloride using combination of nano-ethosomes and iontophoresis: in vitro and in vivo study. Drug Deliv 2016; 23: 1558-64.
20. Gao J, Wang Z, Liu H, Wang L, Huang G. Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. Drug Discov Ther 2015; 9: 205-12.
21. Matsumura Y, Hamaguchi T, Ura T, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle encapsulated doxorubicin. Br J Cancer 2004; 91: 1775-81.
22. Zhang Y, Huang Y, Li S. Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS Pharm Sci Tech 2014; 15; 862-71.
23. Deshpande PP. Current trends in the use of liposomes for tumor targeting. Nanomedicine 2013; 9: 1509-28.
24. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007; 9: E128-47.
25. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Del Rev 2008; 60: 1615-26.
26. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750-63.
27. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7: 771-82.
28. Gao Z, Lukyanov AN, Singhal A, Torchilin VP. Diaclylipid-polymer micelles as nanocarriers for poorly soluble anticancer drugs. Nano Lett 2002; 2: 979-82.
29. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007; 9: 257-88.
30. Salar U, Khan KM, Chigurupeati S, et al. New hybrid scaffold based on hydrazinyl thiazole substituted coumarin; as novel leads of dual potential; in vitro α-amylase inhibitory and antioxidant (DPPH and ABTS radical scavenging) activities. Med Chem 2019; 15: 87-101.
31. Rasouli H, Hosseini-Ghazvini SMB, Adibi H, Khodarahmi R. Differential α-amylase/xglucosidase inhibitory activities of plant-derived phenolic compounds: a virtual screening perspective for the treatment of obesity and diabetes. Food Funct 2017; 8: 1942-54.
32. Kumar R, Duhan M, Kadyan K, Sindhu J, Kumar S, Sharma H. Synthesis of novel inhibitors of alpha-amylase based on the thiazolidine-4-one skeleton containing a pyrazole moiety and their configurational studies. Medchemcomm 2017; 8: 1468-76.
33. Schrödinger Release 2020-2: Prime, Schrödinger, LLC, New York, NY, 2018.
34. Li J, Abel R, Zhu K, Cao Y, Zhao S, Friesner RA. The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. Proteins Struct Funct Bioinforma 2011; 79: 2794-812.
35. Subhani S, Jayaraman A, Jamil K. Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer. Biomed Pharmacother 2015; 71: 37-45.
36. Türe A, Kahraman DC, CETin-Atalay R, Helvacoglu S, Charehsaz M, Kürçügüzel I. Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine–(thio)urea hybrids as potential kinase inhibitors. Comput Biol Chem 2019; 78: 227-41.